Betta Pharmaceuticals Co (SZSE:300558) Total Liabilities : ¥3,714 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Total Liabilities?

Betta Pharmaceuticals Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥3,714 Mil.

Betta Pharmaceuticals Co's quarterly Total Liabilities increased from Sep. 2023 (¥3,485.17 Mil) to Dec. 2023 (¥3,795.44 Mil) but then declined from Dec. 2023 (¥3,795.44 Mil) to Mar. 2024 (¥3,713.62 Mil).

Betta Pharmaceuticals Co's annual Total Liabilities increased from Dec. 2021 (¥1,585.64 Mil) to Dec. 2022 (¥2,952.45 Mil) and increased from Dec. 2022 (¥2,952.45 Mil) to Dec. 2023 (¥3,795.44 Mil).

Betta Pharmaceuticals Co Total Liabilities Historical Data

The historical data trend for Betta Pharmaceuticals Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Total Liabilities Chart

Betta Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,664.12

1,096.12

1,585.64

2,952.45

3,795.44

Betta Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2,980.88	3,447.70	3,485.17	3,795.44	3,713.62

Betta Pharmaceuticals Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Betta Pharmaceuticals Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1803.157	+	(1824.183	+	168.095
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3,795

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	9146.908	-	5351.474
	=	3,795

Betta Pharmaceuticals Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1420.328	+	(2081.829	+	211.463
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3,714

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	9326.46	-	5612.84
	=	3,714

Betta Pharmaceuticals Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Betta Pharmaceuticals Co (SZSE:300558) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN

Website

http://www.bettapharma.com

Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.

Executives

Wang Jia Bing	Directors, executives
Ding Lie Ming	Directors, executives
Cai Wan Yu	Executives

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines